Aclaris Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $4,346 | $2,766 | $2,398 | $17,570 |
Gross Profit | 1,938 | 857 | 558 | 11,142 |
EBITDA | -10,471 | -12,612 | -15,988 | -23,590 |
EBIT | -10,650 | -12,812 | -16,231 | -23,818 |
Net Income | -7,586 | -10,986 | -16,941 | -1,491 |
Net Change In Cash | 4,346 | 2,766 | 2,398 | 17,570 |
Free Cash Flow | 22,000 | -12,308 | -20,950 | -7,202 |
Cash | 47,651 | 22,834 | 35,841 | 39,878 |
Basic Shares | 71,381 | 71,291 | 71,074 | 70,866 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $31,249 | $29,752 | $6,761 | $6,482 |
Gross Profit | 13,168 | 17,792 | 2,048 | 1,349 |
EBITDA | -117,565 | -84,357 | -65,060 | -49,588 |
EBIT | -118,428 | -85,154 | -65,983 | -50,912 |
Net Income | -88,481 | -88,662 | -114,281 | -51,154 |
Net Change In Cash | 31,249 | 29,752 | 6,761 | 6,482 |
Cost of Revenue | 17,928 | 5,286 | -13,874 | |
Free Cash Flow | -79,634 | -68,172 | -52,442 | -39,086 |
Cash | 39,878 | 45,277 | 27,349 | 54,131 |
Basic Shares | 69,808 | 65,213 | 56,730 | 42,539 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.11 |
2024-06-30 | -$0.15 |
2024-03-31 | -$0.24 |
2023-12-31 | -$0.02 |
